UCSF Study Identifies Weakness In Heart Attack Therapy
A UCSF study holds clues to why an emerging clinical trials option for heart attack patients has not been as successful as anticipated. Treatment of human hearts with bone marrow cells has led to limited to no success in improving their heart function even though a similar method has been much more effective in rodents.
Scientists didn´t have a plausible research-based answer until now, according to the UCSF researchers. In a paper published this month in the scientific journal Science Translational Medicine, researchers offer an explanation of why a gap exists been the success of human trials and rodent experiments.
Researchers use bone marrow from young, healthy donor rodents to treat mice that had heart attacks. However in humans, bone marrow cells came from the patients themselves–typically older–after they suffered heart attacks.
“It´s very important to consider the disease, whenever you think about treatments that involve returning cells into the same person from whom they were taken,” said the paper´s senior author Matt Springer, PhD, associate professor of medicine in the UCSF Division of Cardiology and UCSF Cardiovascular Research Institute. “The very disease you´re trying to treat might actually cause a problem for those cells, and that seems to be the case here.
A heart attack occurs about every 20 seconds in the United States with a heart attack death occurring approximately every minute, according to the Centers for Disease Control and Prevention (CDC). That translates to about 500,000 deaths from 1.5 million heart attacks. It is the leading cause of death for men and women in America.
“Heart attacks are very complicated, and are hard to treat even with pharmacology and interventional therapies,” said Xiaoyin Wang, MD, lead author, and an associate research specialist at the UCSF Cardiovascular Research Institute. “It´s difficult to get reasonable and realistic results to heal heart attacks.”
Treatment for heart attacks has had limited success. Once part of the heart tissue dies, the heart becomes weaker and doesn´t function as well as it did before the attack. That´s why Springer and his colleagues created a rodent experiment that closely mimicked real world circumstances.
“Because we cannot easily separate the patient from the disease, we have to use distinct factors such as heart attacks or aging to understand why a trial is successful or not,” Wang said. “But in animal studies, we can easily separate donor and recipient to determine whether heart attacks or aging factors impact bone marrow cells.”
They found cells from donor mice that had a heart attack were impaired, similar to the level of impairment in human bone marrow cells. The researchers also determined that cells from diseased mice were not as effective in reversing the negative effects of a heart attack as those from healthy mice.
“We´ve done a bit of scientific judo,” Springer said. “Mouse experiments use a different donor from the recipient. That can be a disadvantage as a model system. We´re taking that and are using it to our advantage.”
Humans cannot receive bone marrow cells from other human beings because their immune system would naturally fight it, he said. Scientists are also looking at other types of cells for cell therapy, such as stem cells.
Researchers found another obstacle: inflammation caused by heart attack reduced the therapeutic potential of bone marrow cells. Preventing inflammation could be the key in finding an effective heart attack treatment in humans, although many current anti-inflammation treatments cause other risks for heart attack patients.
“We can try to find the parts of the inflammatory response that need to be inhibited without inhibiting the beneficial aspects of the inflammatory response and try to tailor the therapies,” Springer said.
Researchers also hope to better understand which specific cells are problematic for heart attack recovery. Flexibility in a laboratory setting would allow scientists to remove cells to find out if they’re inhibiting recovery. If researchers are able to isolate “bad” cells in rodent experiments, they may hold the key to improving treatment for heart attack patients.
“If we can solve the problem in the mice, it should be translatable to humans,” Springer said.
Researchers believe this study could take them a step closer to finding an effective treatment.
“We´re not saying we´re going to cure heart attacks in five years,” Springer said. “But if we can use studies like this to figure out why therapies are not as good as they could be, and simply do something like use a drug, or change the cells, that could conceivably be used very soon in a clinical trial.”
Co-authors on the paper are Pamela Y. Mok, PhD, Kranthi Pinnamaneni, MD, Daniel J. Haddad, BS, and Brian T. Clifford, BA, of the UCSF Cardiovascular Research Institute; Yerem Yeghiazarians, MD, of the UCSF Divison of Cardiology and Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research; Junya Takagawa, MD, PhD, Yan Zhang, MD, PhD, Robert Su, MD, Shereen A. Saini, BS, Maya J. Bartel, BS, and Richard E. Sievers, BS, of the UCSF Division of Cardiology; Michelle Hermiston, MD, PhD, Viola C. Lam, BS, and Diana L. Tobler, BS, of the UCSF Division of Pediatrics; Larry Carbone, DVM, PhD, of the UCSF Laboratory Animal Resource Center; and Scott Kogan, MD, of the UCSF Department of Laboratory Medicine and Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research..
The study was supported by funds from the NIH and a UC Discovery Grant.
UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.
On the Net: